IOVANCE BIOTHERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

IOVA$8.17+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except per share information)


· · Years Ended December 31,
· · 2025 · · 2024 · · 2023
Revenue
Product revenue, net	$263,502	$164,070	$1,189
Total revenue	263,502	164,070	1,189

Costs and expenses *
Cost of sales **	173,184	93,248	1,033
Research and development **	300,270	276,228	333,194
Selling, general, and administrative **	152,322	152,269	106,098
Depreciation and amortization	35,939	37,603	21,423
Restructuring charges	5,143	—	—
Total costs and expenses	666,858	559,348	461,748
Loss from operations	(403,356)	(395,278)	(460,559)
Other income
Interest and other income, net	10,307	20,273	13,043
Net Loss before income taxes	(393,049)	(375,005)	(447,516)
Income tax (expense) benefit	2,071	2,828	3,479
Net Loss	$(390,978)	$(372,177)	$(444,037)
Net Loss Per Share of Common Stock, Basic and Diluted	$(1.09)	$(1.28)	$(1.89)
Weighted Average Shares of Common Stock Outstanding, Basic and Diluted	357,345	289,877	235,131

* Non-cash stock-based compensation included in cost of sales and operating expenses
Cost of sales	$7,286	$8,554	$—
Research and development	26,959	49,270	34,926
Selling, general and administrative	27,330	51,799	27,699
	$61,575	$109,623	$62,625
** Excludes depreciation and amortization

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.